These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 11125296)
21. The soluble IL-6 receptors: serum levels and biological function. Montero-Julian FA Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):583-97. PubMed ID: 11502067 [TBL] [Abstract][Full Text] [Related]
22. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Wei LH; Kuo ML; Chen CA; Chou CH; Lai KB; Lee CN; Hsieh CY Oncogene; 2003 Mar; 22(10):1517-27. PubMed ID: 12629515 [TBL] [Abstract][Full Text] [Related]
23. Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. Finotto S; Eigenbrod T; Karwot R; Boross I; Doganci A; Ito H; Nishimoto N; Yoshizaki K; Kishimoto T; Rose-John S; Galle PR; Neurath MF Int Immunol; 2007 Jun; 19(6):685-93. PubMed ID: 17496315 [TBL] [Abstract][Full Text] [Related]
24. [Effect of IL-6/sIL-6R on ex vivo expansion of human cord blood derived CD34+ cells]. Feng JF; Zhuang M; Zhu LJ; Sheng ZL; Zhu YQ; Li CP Ai Zheng; 2004 Jun; 23(6):715-8. PubMed ID: 15191679 [TBL] [Abstract][Full Text] [Related]
25. [Advances in the pathogenesis, biology, and management of multiple myeloma]. Kosaka M Rinsho Byori; 1996 Aug; 44(8):743-9. PubMed ID: 8816060 [TBL] [Abstract][Full Text] [Related]
26. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576 [TBL] [Abstract][Full Text] [Related]
27. Update on the pathogenesis of osteolysis in multiple myeloma patients. Giuliani N; Colla S; Rizzoli V Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087 [TBL] [Abstract][Full Text] [Related]
28. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Chen H; Li M; Campbell RA; Burkhardt K; Zhu D; Li SG; Lee HJ; Wang C; Zeng Z; Gordon MS; Bonavida B; Berenson JR Oncogene; 2006 Oct; 25(49):6520-7. PubMed ID: 16702955 [TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984 [TBL] [Abstract][Full Text] [Related]
30. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Leu CM; Wong FH; Chang C; Huang SF; Hu CP Oncogene; 2003 Oct; 22(49):7809-18. PubMed ID: 14586407 [TBL] [Abstract][Full Text] [Related]
31. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416 [TBL] [Abstract][Full Text] [Related]
32. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193 [TBL] [Abstract][Full Text] [Related]
33. Interleukin-6 receptor expression and saturation on the bone marrow cells of patients with multiple myeloma. Brown RD; Gorenc B; Gibson J; Joshua D Leukemia; 1993 Feb; 7(2):221-5. PubMed ID: 8426476 [TBL] [Abstract][Full Text] [Related]
34. The role of human and viral cytokines in the pathogenesis of multiple myeloma. Berenson JR; Sjak-Shie NN; Vescio RA Semin Cancer Biol; 2000 Oct; 10(5):383-91. PubMed ID: 11100886 [TBL] [Abstract][Full Text] [Related]
35. Key differentiation steps in normal B cells and in myeloma cells. Zubler RH Semin Hematol; 1997 Jan; 34(1 Suppl 1):13-22. PubMed ID: 9122741 [TBL] [Abstract][Full Text] [Related]
36. Mechanisms of bone lesions in multiple myeloma. Bataille R; Chappard D; Klein B Hematol Oncol Clin North Am; 1992 Apr; 6(2):285-95. PubMed ID: 1582975 [TBL] [Abstract][Full Text] [Related]
37. New insights in the clinical biology of multiple myeloma. Bataille R Semin Hematol; 1997 Jan; 34(1 Suppl 1):23-8. PubMed ID: 9122743 [TBL] [Abstract][Full Text] [Related]
38. Cytokines as autocrine growth factors in malignancies. Kawano M; Kuramoto A; Hirano T; Kishimoto T Cancer Surv; 1989; 8(4):905-19. PubMed ID: 2701735 [TBL] [Abstract][Full Text] [Related]